Compare · MDT vs NSPR
MDT vs NSPR
Side-by-side comparison of Medtronic plc. (MDT) and InspireMD Inc. (NSPR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. MDT focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus, while NSPR focuses on Medical/Dental Instruments.
- MDT is the larger of the two at $129.18B, about 3608.7x NSPR ($35.8M).
- MDT has been more active in the news (16 items in the past 4 weeks vs 9 for NSPR).
- MDT has more recent analyst coverage (25 ratings vs 1 for NSPR).
- Company
- Medtronic plc.
- InspireMD Inc.
- Price
- -
- -
- Market cap
- $129.18B
- $35.8M
- 1M return
- +7.16%
- -
- 1Y return
- +5.09%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 16
- 9
- Recent ratings
- 25
- 1
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
InspireMD Inc.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.
Latest MDT
- Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
- SEC Form SCHEDULE 13G filed by Medtronic plc.
- Imperative Care Announces Two New Board of Directors Appointments
- Orchestra BioMed Announces Pricing of Public Offering
- Orchestra BioMed Announces Proposed Public Offering
- President Marinaro Michael was granted 6,547 units of Ordinary Shares, increasing direct ownership by 6% to 113,353 units (SEC Form 4)
- Medtronic to announce financial results for its second quarter of fiscal year 2027
- /C O R R E C T I O N - The Michael J. Fox Foundation for Parkinson's Research/
- Michael J. Fox Foundation and Medtronic Partner to Help More People with Parkinson's Understand Deep Brain Stimulation
- Medtronic and Michael J. Fox Foundation Partner to Help More People with Parkinson's Understand Deep Brain Stimulation
Latest NSPR
- InspireMD Announces Pricing of $37.5 Million Public Offering
- SEC Form 424B5 filed by InspireMD Inc.
- InspireMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- InspireMD Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- InspireMD Announces Proposed Public Offering
- InspireMD Reports Third Quarter 2026 Financial Results
- InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures
- InspireMD Announces Updated Timing for Third Quarter 2026 Financial Results
- InspireMD to Announce Third Quarter 2026 Financial Results
- SEC Form 4 filed by Director Roubin Gary S